Neurosense Therapeutics will meet with the FDA in early November to discuss plans for a Phase 3 trial to test PrimeC in ALS.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback